Home › Targets › CCKBR
Radioligand therapy target profile

CCK2R (CCKBR): IHC Expression in Cancer and Radioligand Target Profile

cholecystokinin B receptor · Ensembl ENSG00000110148 · Data updated 2026-11-01
Also known as: CCKBR, CCK-B receptor, Gastrin receptor

CCK2R (CCKBR), cholecystokinin B receptor, is a cell-surface protein (GPCR). No tumor protein staining is recorded for it in Human Protein Atlas immunohistochemistry. Evidence on whether CCK2R internalizes is mixed. Clinical status: Clinical-stage (up to phase 2, any modality).

Is CCK2R the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze CCK2R free
LocalizationCell-Surface
Top cancer (IHC)None detected
InternalizationUncertain
Clinical stageClinical-stage (up to phase 2, any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.16

Is CCK2R a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

CCK2R IHC staining by cancer type

No Human Protein Atlas tumor immunohistochemistry data is available for CCK2R.

Is CCK2R internalized?

Uncertain. Insufficient literature found.

Sources: PMID 34994328 · PMID 33198403 · PMID 33042258 · PMID 23275470 · PMID 17088981. AI-extracted from abstracts, so verify before citing.

CCK2R clinical trials

Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for CCK2R yet. Search ClinicalTrials.gov for CCK2R trials.

CCK2R normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CCK2R in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

CCK2R gene essentiality (DepMap)

CRISPR knockout effect across 1226 cancer cell lines: 0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

See how CCK2R ranks against 15,000 targets for your indication.

Analyze CCK2R free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is CCK2R the right target for your program? · 5 free analyses, no card Analyze CCK2R free